Valeant's 'sales force disruption' puts the hurt on Xifaxan sales

Valeant

Xifaxan isn’t the only one of Valeant’s products that’s underperforming. But the reason behind its underperformance is unique, CEO Joseph Papa maintains.

Earlier this month, the new Valeant chief attributed Xifaxan's slump to “sales force  disruption” over the past 12 months--something the company says it’s been working to address by inserting a new leader and putting a bumped-up sales-force effort behind the med.

“We think that’s going to be an important part of the solution,” Papa told investors on the company’s Q1 conference call.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

It’s certainly a different tune from the one Valeant was singing when it picked up the product. After agreeing to buy out North Carolina-based maker Salix Pharmaceuticals, then-CEO J. Michael Pearson--prone to job-chopping--extolled the virtues of Salix’ rep army as he promised to keep it intact.

“We believe these customer-facing roles have played and will play a huge role in the success of the company," he said.

Now, though, things are different. For one, just this April--amid the announcement of nearly 300 layoffs--Pearson announced that various parts of Valeant’s GI force would be merged, noting in a memo to employees that there could be “new opportunities for some of those affected to take on different roles within the company.”

As a result of all the hullaballoo around personnel--as well as shifts in strategy behind the product--Valeant knocked $390 million off its expected 2016 Xifaxan sales. other drugs, particularly in Valeant’s key dermatology unit, saw their forecasts slashed, too, but an unfavorable distribution agreement with Walgreens triggered much of that change.

The Canadian pharma says it's still optimistic that Xifaxan can make a comeback, especially considering that it boasts indications in both IBS-D and hepatic encephalopathy. For the latter alone, Valeant estimates the total market revenue opportunity in the U.S. checking in at more than $5 billion, Papa said on the call.

- see the call transcript

Special Report: Top 10 animated characters in pharma marketing

Related Articles:
Valeant slashes guidance yet again as Q1 earnings take a beating
Valeant's prized GI force, once shielded from job cuts, faces the ax
Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA

Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.